Amedisys Management

Management criteria checks 1/4

Amedisys' CEO is Richard Ashworth, appointed in Apr 2023, has a tenure of 1.58 years. total yearly compensation is $16.97M, comprised of 4.1% salary and 95.9% bonuses, including company stock and options. directly owns 0.088% of the company’s shares, worth MX$55.76M. The average tenure of the management team and the board of directors is 1.6 years and 5 years respectively.

Key information

Richard Ashworth

Chief executive officer

US$17.0m

Total compensation

CEO salary percentage	4.1%
CEO tenure	1.6yrs
CEO ownership	0.09%
Management average tenure	1.6yrs
Board average tenure	5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Richard Ashworth's remuneration changed compared to Amedisys's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	US$92m
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	US$17m	US$692k	-US$10m

Compensation vs Market: Richard's total compensation ($USD16.97M) is above average for companies of similar size in the MX market ($USD1.35M).

Compensation vs Earnings: Insufficient data to compare Richard's compensation with company performance.

CEO

Richard Ashworth (49 yo)

1.6yrs

Tenure

US$16,974,025

Compensation

Mr. Richard M. Ashworth served as Director at Tivity Health, Inc. since June 1, 2020 until April 2023 and had been its President since June 1, 2020 and served as its Chief Executive Officer since June 1, 2...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Richard Ashworth	President	1.6yrs	US$16.97m	0.088% MX$ 55.8m
Scott Ginn	Executive VP	7.1yrs	US$4.45m	0.077% MX$ 48.7m
Denise Bohnert	Chief Compliance Officer	5.2yrs	US$1.28m	no data
Nick Muscato	Chief Strategy Officer	no data	US$1.37m	0.0065% MX$ 4.1m
Allyson Guidroz	Chief Accounting Officer & Principal Accounting Officer	1.3yrs	no data	0.0097% MX$ 6.1m
Pete Hartley	CTO & Senior VP of Business Operations Systems	no data	no data	no data
Keith Blanchard	Acting Chief Information Officer	less than a year	no data	no data
Jennifer Griffin	Senior VP	2.1yrs	no data	no data
Kendra Kimmons	VP of Marketing & Communications & Media Relations	no data	no data	no data
Caitlin Franklin	Acting Chief People Officer	less than a year	no data	no data
Francis Mayer	Senior Vice President of Development	no data	no data	no data

1.6yrs

Average Tenure

47.5yo

Average Age

Experienced Management: AMED *'s management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Richard Ashworth	President	1.6yrs	US$16.97m	0.088% MX$ 55.8m
Paul Kusserow	Chairman	9.9yrs	US$4.00m	1.33% MX$ 844.9m
Bruce Perkins	Independent Director	9.6yrs	US$267.62k	0.063% MX$ 40.1m
Vickie Capps	Independent Director	5yrs	US$277.62k	0.020% MX$ 12.5m
Molly Coye	Independent Director	5yrs	US$267.62k	0.017% MX$ 10.6m
Julie Klapstein	Lead Independent DIrector	8.6yrs	US$282.62k	0.039% MX$ 24.5m
Jeffrey Rideout	Independent Director	8.6yrs	US$267.62k	0.018% MX$ 11.6m
Teresa Kline	Independent Director	5yrs	US$272.62k	0.020% MX$ 12.5m
Ivanetta Samuels	Independent Director	3.9yrs	US$252.62k	0.013% MX$ 8.2m

5.0yrs

Average Tenure

63yo

Average Age

Experienced Board: AMED *'s board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/11/04 21:37
End of Day Share Price	2024/08/07 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amedisys, Inc. is covered by 32 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Hoffman	Avondale Partners
Matthew Gillmor	Baird
Steven Valiquette	Barclays

Amedisys Management

Management criteria checks 1/4

Key information

Recent management updates

Amedisys, Inc., Annual General Meeting, Dec 30, 2024

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Amedisys, Inc., Annual General Meeting, Dec 30, 2024

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Insufficient new directors

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Insufficient new directors

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Insufficient new directors

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021)

High number of new directors

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

High number of new directors

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

High number of new directors

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

High number of new directors

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

High number of new directors

Investor sentiment deteriorated over the past week

Lead Independent Director recently bought Mex$3.0m worth of stock

Third quarter 2021 earnings released: EPS US$1.38 (vs US$2.20 in 3Q 2020)

Investor sentiment improved over the past week

High number of new directors

High number of new directors

Independent Director recently sold Mex$42m worth of stock

Second quarter 2021 earnings released: EPS US$2.46 (vs US$1.07 in 2Q 2020)

Investor sentiment deteriorated over the past week

High number of new directors

President & COO recently sold Mex$1.5m worth of stock

Amedisys, Inc. (NasdaqGS:AMED) entered into an Agreement to acquire Contessa Health, Inc. for $250 million.

Amedisys, Inc. (NasdaqGS:AMED) entered into a definitive agreement to acquire Home Health and Hospice Operations of Visiting Nurse Association.

Insider recently sold Mex$10m worth of stock

Amedisys, Inc. Provides Revenue Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$1.52 (vs US$0.98 in 1Q 2020)

Amedisys, Inc. and Sound Physicians to Launch Home Health Advanced Pilot Program

Independent Director recently bought Mex$5.3m worth of stock

Revenue misses expectations

Full year 2020 earnings released: EPS US$5.64 (vs US$3.95 in FY 2019)

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Dynamic Index

Amedisys, Inc. and Option Care Health Inc. Collaborate to Provide Innovative COVID Therapy Access Model

Ivanetta Davis Samuels Joins Amedisys, Inc.'s Board of Director

Amedisys, Inc. to Report Q3, 2020 Results on Oct 28, 2020

Amedisys, Inc. to Report Q2, 2020 Results on Jul 28, 2020

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Growth-Defensive Index

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Defensive Index

CEO Compensation Analysis

CEO

Tenure

Compensation